Overview

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The investigators hypothesize that conversion from tacrolimus to sirolimus in renal transplant recipients with DGF/SGF in early months after surgery will improve graft function and decrease the progression of graft fibrosis.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus
Tacrolimus